• 2788 Citations
  • 22 h-Index
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 4 Similar Profiles
Multiple Myeloma Medicine & Life Sciences
Proteasome Inhibitors Medicine & Life Sciences
Interleukin-6 Medicine & Life Sciences
Proteasome Endopeptidase Complex Medicine & Life Sciences
Dexamethasone Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Monoclonal Antibodies Medicine & Life Sciences
Melphalan Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1997 2017

Multiple Myeloma
Maximum Tolerated Dose
Disease-Free Survival

Research Output 2003 2018

A qualitative study of patient and provider perspectives on using web-based pain coping skills training to treat persistent cancer pain

Rini, C., Vu, M. B., Lerner, H., Bloom, C., Carda-Auten, J., Wood, W. A., Basch, E. M., Voorhees, P. M., Reeder-Hayes, K. E. & Keefe, F. J., Apr 1 2018, In : Palliative and Supportive Care. 16, 2, p. 155-169 15 p.

Research output: Contribution to journalArticle

Psychological Adaptation
Focus Groups
Health Personnel
Cancer Pain
2 Citations

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma

Yan, X., Clemens, P. L., Puchalski, T., Lonial, S., Lokhorst, H., Voorhees, P. M., Usmani, S., Richardson, P. G., Plesner, T., Liu, K., Orlowski, R. Z., Losic, N., Jansson, R., Ahmadi, T., Lantz, K., Ruixo, J. J. P., Zhou, H. & Xu, X. S., Apr 1 2018, In : Clinical Pharmacokinetics. 57, 4, p. 529-538 10 p.

Research output: Contribution to journalArticle

1 Citations

Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics

Kamande, J. W., Lindell, M. A. M., Witek, M. A., Voorhees, P. M. & Soper, S. A., Feb 1 2018, In : Integrative Biology (United Kingdom). 10, 2, p. 82-91 10 p.

Research output: Contribution to journalArticle

Plasma Cells
Multiple Myeloma
Monoclonal Gammopathy of Undetermined Significance
Lab-On-A-Chip Devices
6 Citations

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

Laubach, J. P. , Moslehi, J. J. , Francis, S. A. , San Miguel, J. F. , Sonneveld, P. , Orlowski, R. Z. , Moreau, P. , Rosiñol, L. , Faber, E. A. , Voorhees, P. , Mateos, M. V. , Marquez, L. , Feng, H. , Desai, A. , van de Velde, H. , Elliott, J. , Shi, H. , Dow, E. , Jobanputra, N. , Esseltine, D. L. & 4 others Niculescu, L., Anderson, K. C., Lonial, S. & Richardson, P. G., Aug 1 2017, In : British Journal of Haematology. 178, 4, p. 547-560 14 p.

Research output: Contribution to journalArticle

Proteasome Inhibitors
Proteasome Endopeptidase Complex
Multiple Myeloma
Antineoplastic Agents
5 Citations

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma

Friend, R., Bhutani, M., Voorhees, P. M. & Usmani, S. Z., Mar 20 2017, In : Drug Design, Development and Therapy. 11, p. 893-900 8 p.

Research output: Contribution to journalReview article

Multiple Myeloma
Plasma Cells
Immunoglobulin G
Monoclonal Antibodies